Brokerages Set Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Target Price at $41.78

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have been given an average rating of “Moderate Buy” by the ten ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $41.7778.

TEVA has been the subject of several research analyst reports. Barclays upped their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 2nd. Piper Sandler restated an “overweight” rating and issued a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Finally, The Goldman Sachs Group upped their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th.

Teva Pharmaceutical Industries Trading Down 1.1%

Shares of NYSE:TEVA opened at $32.72 on Thursday. Teva Pharmaceutical Industries has a 52 week low of $14.99 and a 52 week high of $37.35. The company’s 50 day moving average is $32.62 and its two-hundred day moving average is $31.55. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The company has a market cap of $37.62 billion, a PE ratio of 24.60, a P/E/G ratio of 3.37 and a beta of 0.84.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The company had revenue of $3.98 billion for the quarter. Equities analysts predict that Teva Pharmaceutical Industries will post 2.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the completion of the sale, the executive vice president owned 172,184 shares in the company, valued at $6,131,472.24. This represents a 47.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Richard Daniell sold 30,000 shares of the stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the sale, the executive vice president owned 55,755 shares of the company’s stock, valued at approximately $1,973,727. This represents a 34.98% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 421,470 shares of company stock worth $14,570,945. 0.54% of the stock is currently owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

A number of large investors have recently bought and sold shares of TEVA. AQR Capital Management LLC raised its position in Teva Pharmaceutical Industries by 24.6% during the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after buying an additional 4,732 shares during the last quarter. Focus Partners Wealth raised its position in Teva Pharmaceutical Industries by 4.5% during the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after buying an additional 1,739 shares during the last quarter. Franklin Resources Inc. purchased a new position in Teva Pharmaceutical Industries during the 2nd quarter worth $255,000. Flow Traders U.S. LLC purchased a new position in Teva Pharmaceutical Industries during the 2nd quarter worth $238,000. Finally, Cerity Partners LLC raised its position in Teva Pharmaceutical Industries by 2.9% during the 2nd quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock worth $768,000 after buying an additional 1,291 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.